Georgiamune

Georgiamune Inc., a clinical-stage biotechnology company located in Gaithersburg, Maryland, focuses on reprogramming immune signaling pathways to redirect the immune system to combat diseases, dedicating efforts in the fields of oncology and autoimmune diseases. The company also announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for GIM-122, a bifunctional monoclonal antibody.